Therapeutic area intelligence for FLT3 Inhibitor with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

VANFLYTA →

Recent signals(2)

RegulatoryAugust 1, 2026

FDA Accepts Supplement Application for VANFLYTA by Daiichi Sankyo

The FDA has accepted a supplemental application for VANFLYTA (quizartinib dihydrochloride) from Daiichi Sankyo.

RegulatoryJuly 8, 2026

FDA Accepts Supplement Application for VANFLYTA (Quizartinib)

The FDA has accepted a supplemental application for VANFLYTA, a drug containing quizartinib dihydrochloride.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.